Clinical trials: Healthy Blood Donors
Hematologic Disease and Disorders, Donors
Screening for Hematology Branch Protocols
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.
- Conditions
- Hematologic Disease and Disorders, Donors, Healthy Volunteer
- Trial name
- NCT00001620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Thrombocytopenia
Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus
Plasma histidine-rich glycoprotein (HRG) binds to platelets in the presence of zinc (1). This binding is totally blocked by a monoclonal antibody directed against platelet membrane CD36.
- Trial name
- NCT00015639
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatitis E
Seroprevalence Hepatitis E Infection in Healthy Blood Donors
This is a HEV seroprevalence in the health donors in the Canton Ticino study. The pre-donation sampling pouch of each blood donor coming form the Cantone Ticino region will be collected and tested for HEV serology (IgM and IgG).
- Trial name
- NCT03601221
- Testing
- Sample collection
- Where
- Switzerland
- Volunteers
- 1,447 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Healthy
G-CSF for Granulocyte Donation
This study will examine the feasibility of giving cell growth stimulants to granulocyte donors the same day of donation rather than the day before.
- Trial name
- NCT00001842
- Testing
- Granulocyte colony-stimulating factor, Dexamethasone
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Healthy Blood Donors, Moli-sani Subjects
Hypercoagulation Screening in Cancer
There is a complex, mutual relationship between cancer and thrombosis. Indeed, the tumor has the capacity to activate the hemostatic system and this leads to an increased thrombotic risk in cancer patients.
- Conditions
- Healthy Blood Donors, Moli-sani Subjects, Cancer Patients
- Trial name
- HYPERCAN (NCT02622815)
- Where
- 8 sites in Italy
- Volunteers
- 16,000 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Healthy Donors, HIV Positive
Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay
To test blood samples from volunteer donors of whole blood and blood components using a new investigational test that detects human immunodeficiency virus (HIV) infection.
- Trial name
- NCT00686205
- Testing
- collection of follow-up sample based on PRISM HIV O Plus result
- Where
- 7 sites in United States
- Volunteers
- 24,111 people, healthy volunteers welcome
- Sponsor
- Abbott Diagnostics Division
HIV Infections, Healthy
Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines
Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to synthetic peptides…
- Trial name
- NCT00001210
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
Background: Bone marrow stem cells, which are found in the bone marrow and blood stream, can be collected and transplanted to treat a variety of types of cancer in a process known as hematopoietic stem cell transplantation…
- Trial name
- NCT01287104
- Testing
- Natural Killer (NK) Cell Infusion, Stem Cell Infusion
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)